News

Managed Healthcare Executive23h
Pfizer’s Hympavzi Cuts Bleeding by 93% in Hemophilia A and B Patients with Inhibitors, Phase 3 Trial Finds
Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...
Pfizer Advances HYMPAVZI After Successful Hemophilia Trial Results
Pfizer Inc. (NYSE:PFE) ranks among the best set-it-and-forget-it stocks to buy. On June 26, Pfizer Inc. (NYSE:PFE) declared ...